---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-25-000082"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T18:15:06.964809+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GRI Bio reports positive interim safety results from Phase 2a IPF study; IDMC recommends continuation

## Summary
- IDMC recommends study continue after no safety concerns in first 24 patients evaluated at 6 weeks.
- GRI-0621 safe and well-tolerated; no adverse events related to hyperlipidemia (LDL, HDL, TG).
- No clinically meaningful changes in HDL, LDL, or TG levels; all subjects within protocol ranges.
- Interim biomarker data expected July 2025; topline results from Phase 2a study expected Q3 2025.

## SEC filing metadata
- accession: 0001824293-25-000082
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429325000082/0001824293-25-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429325000082/val-20250626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-25-000082
- JSON: https://secwatch.observer/filing/0001824293-25-000082.json
- Plain text: https://secwatch.observer/filing/0001824293-25-000082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.